WACKER said Foster Corporation, under terms of the agreement, will provide customers locally available professional sales, technical and fulfillment support through their two regional stocking facilities in the continental United States. Foster Corporation is currently preparing inventory stock and is to begin processing and shipping orders effective March 1, 2017.
According to Scott Borst, WACKER Senior Director - Engineering Silicones, Foster Corporation is a strategic addition to WACKER’s distribution business model, further adding strength and depth to already well-established sales and technical teams. “By combining our resources and working in close collaboration, WACKER and Foster Corporation will be able to offer the medical device market an available and reliable source of SILPURAN® products,” Borst explained. “Timely delivery and flexible order size will be key benefits. Additionally, upgrading customer contact and corresponding technical support are among our important business considerations. WACKER is a recognized global leader in silicone chemistry. Partnerships such as between WACKER and Foster Corporation are in line with bringing customers the best possible silicone-based product solutions and overall service.”
”We believe the relationship between WACKER and Foster will mature into a win-win situation across the board,” said Larry Johnson, VP Business Development, Foster Corporation. “First and foremost, customers will have easy access to WACKER’s comprehensive medical-grade silicone product line for existing and potential new applications. For WACKER, additional focused business development for silicone products designed for medical devices and health care applications will create opportunity for expanding its overall customer base. And for Foster, the addition of silicone-based materials is a great complement to our current polymer offering, giving customers a wide range of selection and availability.”
About Foster Corporation
Foster Corporation is a global provider of biomedical material solutions for “critical” medical, pharmaceutical, and bioscience applications. Business platforms include customized development & manufacture of compounded medical polymers for class I, II, and III applications, distribution of medical polymers, and additional pharmaceuticals into polymer matrices for drug delivery applications.